Novanta Inc.

NasdaqGS:NOVT Aktierapport

Börsvärde: US$5.5b

Novanta Tidigare resultatutveckling

Tidigare kriterier kontrolleras 1/6

Novanta har ökat intäkterna med en genomsnittlig årlig takt på 2.3%, medan Electronic -branschen såg intäkterna växer på 3.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 8.5% per år. Novanta s avkastning på eget kapital är 4.1% och den har en nettomarginal på 5.3%.

Viktig information

2.30%

Tillväxttakt i vinsten

1.63%

Tillväxttakt för EPS

Electronic Tillväxt i branschen15.34%
Intäkternas tillväxttakt8.52%
Avkastning på eget kapital4.10%
Nettomarginal5.35%
Senaste uppdateringen av resultatet03 Apr 2026

Senaste uppdateringar av tidigare prestationer

Recent updates

Uppdatering av berättelse Jun 17

NOVT: Future Earnings Power Will Rely On Executing Riverpoint Acquisition Strategy

Analysts have adjusted their fair value estimate for Novanta to $175.0 from $171.5, citing updated models that incorporate recent Q1 results, accelerating bookings and growth momentum, along with a revised future P/E assumption of 34.67x. Analyst Commentary Recent Street commentary on Novanta focuses on how the latest Q1 results and updated models feed into valuation, execution risk and future growth assumptions for the stock.
Seeking Alpha Jun 11

Novanta: An Interesting Deal Accelerates Growth

Summary Novanta announced a substantial $1.45B acquisition of Riverpoint Medical, doubling recurring medical consumables revenue and increasing medical end-market concentration to 60%. Riverpoint brings high-margin, fast-growing consumables, with 12-15% organic growth and 40% EBITDA margins, enhancing Novanta's profitability profile. Pro forma leverage rises to 2.7x; a $300M equity raise at a discount offsets some debt but results in 3% dilution. Despite strong execution and growth momentum, Novanta trades at ~40x forward earnings, leading me to remain cautious and await better entry points. Read the full article on Seeking Alpha
Uppdatering av berättelse Jun 02

NOVT: Future Earnings Power Will Rely On Sustaining Bookings Strength And Margin Execution

Analysts have lifted their fair value estimate for Novanta stock from $157 to about $171.50, citing updated models that reflect Q1 results with accelerating bookings and ongoing growth momentum. Analyst Commentary Bullish Takeaways Bullish analysts point to accelerating Q1 bookings as a key support for a higher fair value range, seeing healthier near term demand feeding into updated models.
Analysartikel May 15

Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

It's been a pretty great week for Novanta Inc. ( NASDAQ:NOVT ) shareholders, with its shares surging 14% to US$156 in...
Uppdatering av berättelse Apr 19

NOVT: Future Earnings Power Will Rely On Executing Stronger Margins

Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.
Uppdatering av berättelse Apr 05

NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins

Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.
Uppdatering av berättelse Mar 22

NOVT: Future Earnings Power Will Rely On Accelerating Margins

Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.
Uppdatering av berättelse Mar 06

NOVT: Future Earnings Power Will Rely On Accelerating Margins

Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.
Uppdatering av berättelse Feb 20

NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple

Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.
Uppdatering av berättelse Feb 06

NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals

Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).
Uppdatering av berättelse Jan 22

NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals

Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.
Uppdatering av berättelse Jan 08

NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals

Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.
Uppdatering av berättelse Dec 24

NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals

Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.
Uppdatering av berättelse Dec 10

NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value

Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).
Uppdatering av berättelse Nov 26

NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward

Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.
Uppdatering av berättelse Nov 10

NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside

Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.
Analysartikel Oct 28

Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump

Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
Analysartikel Oct 07

Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?

Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...
Analysartikel Sep 13

Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
Uppdatering av berättelse Sep 05

Robotics And Healthcare Demand Will Expand Market Opportunities

Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.
Analysartikel Aug 29

Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion

With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...
Seeking Alpha Apr 06

Novanta: A Trusted Yet Premium Technology Partner

Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking Alpha
Seeking Alpha Jan 01

Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell

Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking Alpha
Seeking Alpha Sep 02

Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold

Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
User avatar
Ny berättelse Aug 28

Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth

Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.

Fördelning av intäkter och kostnader

Hur Novanta tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.


Resultat- och intäktshistorik

NasdaqGS:NOVT Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
03 Apr 261,0055420595
31 Dec 259815419695
26 Sep 259605318898
27 Jun 259576118197
28 Mar 259527117996
31 Dec 249496417796
27 Sep 249236017594
28 Jun 249006217092
29 Mar 248936916892
31 Dec 238827316592
29 Sep 238887616190
30 Jun 238907716289
31 Mar 238767316088
31 Dec 228617415986
30 Sep 228417315683
01 Jul 227966414779
01 Apr 227485813775
31 Dec 217075013073
01 Oct 216554912269
02 Jul 216214411767
02 Apr 215984411164
31 Dec 205914511061
02 Oct 206034111260
03 Jul 206144211358
03 Apr 206244011857
31 Dec 196264111956
27 Sep 196234311754
28 Jun 196295611954
29 Mar 196255711953
31 Dec 186145111651
28 Sep 186053911550
29 Jun 185911811348
30 Mar 185591210844
31 Dec 175214010242
29 Sep 17473489438
30 Jun 17425558634
31 Mar 17403548233
31 Dec 16385228132
30 Sep 16376208031
01 Jul 16371198031
01 Apr 16369348131
31 Dec 15374368231
02 Oct 1537718532
03 Jul 1538008632

Kvalitetsintäkter: NOVT har en stor engång förlust av $27.7M {1 månader till 3rd April, 2026 1 månader) 3rd April, 2026.

Växande vinstmarginal: NOVT s nuvarande netto vinstmarginaler (5.3%) är lägre än förra året (7.4%).


Fritt kassaflöde vs resultatanalys


Analys av tidigare vinsttillväxt

Resultatutveckling: NOVT s intäkter har ökat med 2.3% per år under de senaste 5 åren.

Accelererande tillväxt: NOVT s har haft negativ intäktstillväxt under det senaste året, så det kan inte jämföras med dess 5-åriga genomsnitt.

Resultat vs industri: NOVT hade negativ intäktstillväxt ( -23.3% ) under det senaste året, vilket gör det svårt att jämföra med branschens genomsnitt Electronic ( 11.8% ).


Avkastning på eget kapital

Hög ROE: NOVT s avkastning på eget kapital ( 4.1% ) anses vara låg.


Avkastning på tillgångar


Avkastning på sysselsatt kapital


Upptäck starka bolag som tidigare presterat bra

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/17 15:58
Aktiekurs vid dagens slut2026/06/17 00:00
Intäkter2026/04/03
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Novanta Inc. bevakas av 8 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Robert MasonBaird
Quinn FredricksonBaird
Andrew BuscagliaBerenberg